# An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.

> **NCT00699608** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 91 (actual)

## Conditions studied

- Healthy Subjects
- Sleep Initiation and Maintenance Disorders

## Interventions

- **DRUG:** GSK1755165; placebo; zopiclone

## Key facts

- **NCT ID:** NCT00699608
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2012-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00699608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00699608, "An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00699608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*